HK1089772A1 - Particle-forming compositions containing fused pyrrolocarbazoles - Google Patents

Particle-forming compositions containing fused pyrrolocarbazoles

Info

Publication number
HK1089772A1
HK1089772A1 HK06111691.3A HK06111691A HK1089772A1 HK 1089772 A1 HK1089772 A1 HK 1089772A1 HK 06111691 A HK06111691 A HK 06111691A HK 1089772 A1 HK1089772 A1 HK 1089772A1
Authority
HK
Hong Kong
Prior art keywords
particle
compositions containing
forming
forming compositions
containing fused
Prior art date
Application number
HK06111691.3A
Other languages
English (en)
Inventor
Dave Dickason
Bradley T Mcintyre
Piyush R Patel
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of HK1089772A1 publication Critical patent/HK1089772A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK06111691.3A 2003-11-20 2006-10-24 Particle-forming compositions containing fused pyrrolocarbazoles HK1089772A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/718,077 US7795246B2 (en) 1998-08-06 2003-11-20 Particle-forming compositions containing fused pyrrolocarbazoles
PCT/US2004/037928 WO2005051958A2 (en) 2003-11-20 2004-11-12 Particle-forming compositions containing fused pyrrolocarbazoles

Publications (1)

Publication Number Publication Date
HK1089772A1 true HK1089772A1 (en) 2006-12-08

Family

ID=34633209

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06111691.3A HK1089772A1 (en) 2003-11-20 2006-10-24 Particle-forming compositions containing fused pyrrolocarbazoles

Country Status (21)

Country Link
US (1) US7795246B2 (ko)
EP (1) EP1685137B1 (ko)
JP (1) JP2007512333A (ko)
KR (1) KR20070006674A (ko)
CN (1) CN1882594A (ko)
AT (1) ATE520697T1 (ko)
AU (1) AU2004292524A1 (ko)
BR (1) BRPI0416733A (ko)
CA (1) CA2545545A1 (ko)
EA (2) EA014713B1 (ko)
ES (1) ES2369365T3 (ko)
HK (1) HK1089772A1 (ko)
IL (1) IL175374A0 (ko)
IS (1) IS8486A (ko)
MX (1) MXPA06005714A (ko)
NO (1) NO20062381L (ko)
NZ (2) NZ577384A (ko)
SG (1) SG148175A1 (ko)
UA (1) UA87121C2 (ko)
WO (1) WO2005051958A2 (ko)
ZA (1) ZA200604072B (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016289856B2 (en) 2015-07-07 2020-11-26 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
SI3801526T1 (sl) 2018-05-25 2024-05-31 Cardurion Pharmaceuticals, Inc. Monohidratne in kristalinične oblike 6-((3s, 4s)-4-metil-1-(pirimidin-2-ilmetil)pirolidin-3-il)-3-tetrahidropiran-4- il-7h-imidazo (1.5 - a) pirazin-8-ona

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62120388A (ja) 1985-11-19 1987-06-01 Meiji Seika Kaisha Ltd Ｓｆ−２３７０物質ハロゲン化誘導体とその製造法
JPS62155285A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62155284A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPH0826037B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
JPH0826036B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
EP0303697B1 (en) 1987-03-09 1997-10-01 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
DE3924538A1 (de) * 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
JP2937446B2 (ja) 1990-09-14 1999-08-23 株式会社資生堂 白髪防止黒化剤
NZ242467A (en) 1991-07-03 1995-06-27 Regeneron Pharma Methods and compositions using oligonucleotides to treat mammalian tumour cells expressing neurotrophic factors
AU3064992A (en) 1991-11-08 1993-06-07 University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5621100A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5621101A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5516771A (en) * 1993-05-28 1996-05-14 Cephalon, Inc. Use of indolocarbazole derivatives to treat a pathological condition of the prostate
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
GB9325395D0 (en) 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
WO1995022331A1 (en) * 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
EP0711556A1 (de) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Intravenöse Lösungen für ein Staurosporinderivat
EP0733372A3 (de) * 1995-03-21 1998-05-20 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage für Nanosuspensionen
JPH08301762A (ja) * 1995-05-12 1996-11-19 Teijin Ltd 肺癌治療剤
JPH08333245A (ja) * 1995-06-07 1996-12-17 Taisho Pharmaceut Co Ltd イブプロフェン懸濁液剤
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
DK0850646T3 (da) 1996-06-18 2008-05-13 Kyowa Hakko Kogyo Kk Liposompræparater af indolocarbazol-derivater
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
ATE417608T1 (de) * 2000-10-11 2009-01-15 Cephalon Inc Arzneizusammensetzungen enthaltend modafinilverbindungen

Also Published As

Publication number Publication date
US7795246B2 (en) 2010-09-14
ATE520697T1 (de) 2011-09-15
EP1685137A2 (en) 2006-08-02
AU2004292524A1 (en) 2005-06-09
WO2005051958A3 (en) 2006-01-12
ES2369365T3 (es) 2011-11-29
SG148175A1 (en) 2008-12-31
ZA200604072B (en) 2007-09-26
NO20062381L (no) 2006-06-09
EP1685137B1 (en) 2011-08-17
EA014713B1 (ru) 2011-02-28
BRPI0416733A (pt) 2007-01-16
CN1882594A (zh) 2006-12-20
MXPA06005714A (es) 2006-08-17
CA2545545A1 (en) 2005-06-09
UA87121C2 (ru) 2009-06-25
EA010293B1 (ru) 2008-08-29
EA200800923A1 (ru) 2008-08-29
IL175374A0 (en) 2006-09-05
NZ547225A (en) 2009-06-26
NZ577384A (en) 2010-12-24
KR20070006674A (ko) 2007-01-11
US20040220176A1 (en) 2004-11-04
IS8486A (is) 2006-05-26
JP2007512333A (ja) 2007-05-17
EA200601004A1 (ru) 2006-10-27
WO2005051958A2 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
CY1107855T1 (el) Συνθεσεις που σχηματιζουν σωματιδια οι οποιες περιεχουν τηγμενα πυρρολοκαρβαζολια
WO2004092135A3 (en) Substituted benzosulphonamide as potentiators of glutamate receptors
IL142254A0 (en) Method for the preparation of stable suspensions of single carbon nanotubes
TW200508224A (en) Cyclic derivatives as modulators of chemokine receptor activity
WO2005020899A3 (en) Substituted cycloalkyamine derivatives as modulators of chemokine receptor activity
WO2002071827A3 (en) Retinoid x receptor modulators
NO20062377L (no) CCR-2-antagonistsalt
AU2003296668A1 (en) Sodium percarbonate particles with improved storage stability
MX2009002433A (es) Agente de control de pestes en la forma de suspension estable.
MXPA02011319A (es) Analogos antitumorales de ecteinascidina 743.
MY129564A (en) Compositions comprising cefuroxime axetil
WO2004098516A3 (en) Cyclic derivatives as modulators of chemokine receptor activity
DE60201523D1 (de) Dichtsichtige dispersionen
WO2004092100A8 (en) Indene derivatives as pharmaceutical agents
NO20021409D0 (no) Hastighets-kontrollerte partikler
HK1089772A1 (en) Particle-forming compositions containing fused pyrrolocarbazoles
AU2002362761A1 (en) Generation of virus-like particles by vsv
AU2002218075A1 (en) Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them
EA200300727A1 (ru) Производные 2h-1-бензопирана, способы их получения и их фармацевтические композиции
AU2003277398A1 (en) Methods for assessment of platelet aggregation
MXPA02012589A (es) Compuestos utiles para la preparacion de medicamentos con actividad inhibitoria de la fosfodiesterasa iv.
MXPA05013433A (es) Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato.
AU2002226616A1 (en) Preparation of pure 3-alkoxymethyl cephalosporins.
AU2002363085A1 (en) Chemical modification of particle surfaces by cross-linking
Karas et al. Numerical simulation of shaping the stationary nonequilibrium distributions of particles with Coulomb interactions; Chislennoe modelirovanie formirovaniya statsionarnykh neravnovesnykh raspredelenij kulonovskikh vzaimodejstvuyushchikh chastits

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20171112